Diagnosis and treatment of paraneoplastic neurological syndromes

Current Clinical Pharmacology

Volumn 3, Issue 1, 2008, Pages 46-50

  Vitaliani, Roberta ^a,b   Zoccarato, Marco ^a   Giometto, Bruno ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Treviso General Hospital   (Italy)

Author keywords

Anti neuronal antibodies; Autoimmunity; Paraneoplastic neurological syndromes; Therapy; Tumor

Indexed keywords

AMPHIPHYSIN; ANTICONVULSIVE AGENT; BACLOFEN; CARBAMAZEPINE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CYCLOPHOSPHAMIDE; DIAZEPAM; FLUORODEOXYGLUCOSE; GEPHYRIN; HU ANTIBODY; IMMUNOGLOBULIN G; METABOTROPIC RECEPTOR 1; NEOSTIGMINE; NICOTINIC RECEPTOR; OPIATE; PHENYTOIN; RECOVERIN; STEROID; THIAMINE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VIGABATRIN; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED POTASSIUM CHANNEL;

ANTIBODY DETECTION; ANTIGEN EXPRESSION; AUTONOMIC NEUROPATHY; CANCER IMMUNOTHERAPY; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; EATON LAMBERT SYNDROME; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; MUSCLE SPASM; MYASTHENIA GRAVIS; MYOCLONUS; MYOKYMIA; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPSOCLONUS; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PARANEOPLASTIC NEUROPATHY; PLASMAPHERESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; REVIEW; SENSORY NEUROPATHY; STIFF MAN SYNDROME; TESTIS CANCER;

AUTOIMMUNITY; HUMANS; PARANEOPLASTIC SYNDROMES, NERVOUS SYSTEM;

EID: 38949195063     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408783329922     Document Type: Review

References (33)

1. Darnell RB, Posner JB. Paraneoplastic neurological syndromes involving the central nervous system. N Engl J Med 2003; 349: 1543-54.
2. Posner JB. In: Posner JB Ed, Neurologic Complications of Cancer. Philadelphia, FA Davis Co. 1995; 353-85.
3. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumor association in 50 patients. Brain 2000; 123: 1481-94.
4. Shams'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-18.
5. Posner JB. Paraneoplastic opsoclonus/myoclonus: B cells, T cells, both, or neither? Neurology 2004; 62(9): 1466-7.
6. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001; 24: 1138-48.
7. Rudniki SA, Dalmau J. Paraneoplastic syndromes of the peripheral nerves. Curr Opin Neurol 2005; 18: 598-603.
8. Carpentier AF, Delattre JY. The Lambert-Eaton Myasthenic Syndrome. Clin. Rev. All. Immunol 2001; 20: 155-8.
9. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, Evans SR, Felson DT. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
10. Graus F, Bonaventura I, Uchuya M, et al. An indolent anti-Hu-associated paraneoplastic sensory neuropathy. Neurology 1994; 44: 2258-61.
11. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 2004; 56: 715-9.
12. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 2004; 75: 1135-40.
13. Lawn ND, Westmoreland BF, Kieley MJ, Lennon VA, Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in Paraneoplastic Limbic Encephalitis. Mayo Clin Proc 2003; 78: 1363-8.
14. Crotty E, Patz EF. FDG-PET imaging in patients with paraneoplastic neurological syndrome and suspected small cell lung cancer. J Thorac Imaging 2001; 16: 89-93.
15. Battaler L, Graus F, Uchuya M, Vilchez JJ; Spanish Opsoclonus-Myoclonus Study Group. Clinical outcome in adult onset idiopathic or paraneoplastic opsoclonus-myoclonus. Brain 2001; 124: 1481-94.
16. Altman AJ, Baehener RL. Favourable prognosis for survival in children with coincident opsoclonus-myoclonus and neuroblastoma. Cancer 1976; 37: 846-52.
17. Sham'ili S, Grefkens J, de Leeuw B, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients. Brain 2003; 126: 1409-18.
18. Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Semin Neurol 2003; 23(2): 215-24.
19. Vernino S. Autoimmune and paraneoplastic channelopathies. Neurotherapeutics 2007; 4 (2): 305-14.
20. Voltz R. Intravenus immunoglobulin therapy in paraneoplastic neurological syndromes. J Neurol 2006; 253: 33-8.
21. Batchelor TT, Platten M, Hochberg FH. Immunoadsorption therapy for paraneoplastic syndromes. J Neurooncol 1998; 40: 131-6.
22. Newsom Davis J. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Semin Neurol 2003; 23(2): 191-8.
23. Shams'ili S, de Beukelaar J, Gratama JW, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol 2006; 253: 16-20.
24. Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol 2004; 6: 55-62.
25. Yiu VW, Kovithavongs T, McGonigle LF, Ferreira P. Plasmapheresis as an effective treatment for opsoclonus-myoclonus syndrome. Pediatr Neurol 2001; 24: 72-4.
26. Kos PS, Raffaelenspenger JG, Berry S, et al. Long term clinical outcome in children with opsoclonus myoclonus and ataxia and coincidental neuroblastoma. J Pediatr 1994; 1125: 712-6.
27. Dropcho EJ, Kline LB, Riser J, Antineuronal (anti-Ri) antibodies in a patient with steroid responsive opsoclonus-myoclonus. Neurology 1993; 43: 207-11.
28. Vincent A, Buckley C, Schott JM, et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain 2004; 127: 701-12.
29. Dalmau J, Graus F, Villarejo A, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain 2004; 127: 1831-44.
30. Kleim-Gluibert F, Graus F, Fleury A, et al. Treatment of paraneoplastic syndrome with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide and methylprednisone. J Neurol Neurosurg Psychiatry 2000; 68: 479-82.
31. Oh SJ, Dropcho EJ, Claussen GC. Anti-Hu associated paraneoplastic sensory neuronopathy responding to early aggressive immunotherapy: report of two cases and review of the literature. Muscle Nerve 1997; 20: 1576-82.
32. Graus F, Kleime-Guibert F, Renè R, et al. Anti-Hu associated encephalomyelitis: analysis of 200 patients. Brain 2001; 124: 1138-48.
33. Vedeler CA, Antoine JC, Giometto B, et al. Paraneoplastic Neurological Syndrome Euronetwork. Management of paraneoplastic neurological syndromes; report of an EFNS Task Force. Eur J Neurol 2006; 13: 682-90.